| Drug General Information |
| Drug ID |
D0YA6U
|
| Former ID |
DIB012243
|
| Drug Name |
ELN-864709
|
| Synonyms |
ELN-330977; ELN-678033; ELN-864709; JNK3 inhibitors (neuronal injury), Elan; JNK3 inhibitors (neuronalinjury/neurodegenerative disease); JNK3 inhibitors (neuronal injury/neurodegenerative disease), Elan
|
| Indication |
Central nervous system injury [ICD10:P11.9]
|
Investigative |
[1]
|
|---|
| Company |
Elan Corp plc
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Canonical SMILES |
Clc1csc(c1c1n[nH]cn1)NC(=O)Cc1c2ccncc2ccc1
|
| Target and Pathway |
| Target(s) |
Mitogen-activated protein kinase 10 |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
ErbB signaling pathway
|
|
Ras signaling pathway
|
|
cAMP signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Protein processing in endoplasmic reticulum
|
|
Wnt signaling pathway
|
|
Osteoclast differentiation
|
|
Focal adhesion
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
Insulin signaling pathway
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Adipocytokine signaling pathway
|
|
Type II diabetes mellitus
|
|
Non-alcoholic fatty liver disease (NAFLD)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Hepatitis B
|
|
Influenza A
|
|
Herpes simplex infection
|
|
Epstein-Barr virus infection
|
|
Pathways in cancer
|
|
Colorectal cancer
|
|
Pancreatic cancer
|
|
Choline metabolism in cancer
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Apoptosis signaling pathway
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
FAS signaling pathway
|
|
FGF signaling pathway
|
|
Integrin signalling pathway
|
|
Interferon-gamma signaling pathway
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
Ras Pathway
|
|
CCKR signaling map ST
|
|
Pathway Interaction Database
|
Noncanonical Wnt signaling pathway
|
|
CD40/CD40L signaling
|
|
FAS (CD95) signaling pathway
|
|
Glucocorticoid receptor regulatory network
|
|
FoxO family signaling
|
|
p75(NTR)-mediated signaling
|
|
ErbB2/ErbB3 signaling events
|
|
PDGFR-beta signaling pathway
|
|
Nephrin/Neph1 signaling in the kidney podocyte
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
FCERI mediated MAPK activation
|
|
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
|
|
Activation of the AP-1 family of transcription factors
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
DNA Damage Response (only ATM dependent)
|
|
G13 Signaling Pathway
|
|
Insulin Signaling
|
|
Wnt Signaling Pathway
|
|
MAPK Cascade
|
|
Oxidative Stress
|
|
Wnt Signaling Pathway and Pluripotency
|
|
Apoptosis Modulation by HSP70
|
|
MAPK Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Structural Pathway of Interleukin 1 (IL-1)
|
|
Apoptosis
|
|
BDNF signaling pathway
|
|
Integrin-mediated Cell Adhesion
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1498). |
|---|
